MedDataX Logo

Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 2 Diabetes Mellitus Also Using Insulin Glargine

NCT ID: NCT02294474

Last Updated: 2018-01-18

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

505 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-01-31

Study Completion Date

2016-02-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Primary Objective:

To demonstrate non-inferiority of SAR342434 versus Humalog in glycated hemoglobin A1c (HbA1c) change from baseline to Week 26 in participants with type 2 diabetes mellitus (T2DM) also using insulin glargine.

Secondary Objectives:

To assess the immunogenicity of SAR342434 and Humalog in terms of positive/negative status and antibody titers at baseline and during the course of the study; To assess the relationship of anti-insulin antibodies with efficacy and safety. To assess the efficacy of SAR342434 and Humalog on: proportion of participants reaching target HbA1c \<7.0% and \<=6.5%, fasting plasma glucose (FPG) and self-measured plasma glucose (SMPG) profiles, and insulin dose.

To assess safety of SAR342434 and Humalog.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine

NCT02273180

Type 1 Diabetes Mellitus
COMPLETED PHASE3

Comparison of SAR341402 to NovoLog/NovoRapid in Adult Patients With Diabetes Mellitus Also Using Insulin Glargine

NCT03211858

Type 1 Diabetes Mellitus-Type 2 Diabetes Mellitus
COMPLETED PHASE3

A Study to Compare Pharmacokinetics and Pharmacodynamics of SAR342434 to Insulin Lispro in Subjects With Type 1 Diabetes

NCT02273258

Type 1 Diabetes
COMPLETED PHASE1

Comparison of SAR341402 to NovoLog in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine

NCT03874715

Type 1 Diabetes Mellitus
COMPLETED PHASE3

A Research Study to See How Switching From a Daily Basal Insulin to a New Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine in Adults With Type 2 Diabetes

NCT06340854

Diabetes, Type 2
COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study will consist of a: up to 2 weeks screening period, 26-week treatment period, and 1-day follow-up period.

The maximum study duration will then be 28 weeks per participant and a 1-day safety follow-up.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Type 2 Diabetes Mellitus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

SAR342434

SAR342434 100 Unit/mL (U/mL) before meals intake on top of once daily (QD) Insulin Glargine, up to Week 26.

Group Type EXPERIMENTAL

SAR342434

Intervention Type DRUG

SAR342434 100 U/mL (dose range of 1 Unit to 80 Units) self-administered by subcutaneous (SC) injection, immediately (within 5 -10 minutes) before meals intake. Dose adjusted to achieve 2 hour post prandial glucose (PPG) in range of 6.7 to 8.9 mmol/L (120 to 160 mg/dL) while avoiding hypoglycemia.

insulin glargine HOE901

Intervention Type DRUG

Insulin glargine 100 U/mL injected QD subcutaneously consistent with the local label. Doses adjusted to achieve glycemic target for fasting, preprandial plasma glucose (SMPG) between 4.4 to 7.2 mmol/L (80 to 130 mg/dL) without hypoglycemia.

Humalog

Humalog 100 U/mL before meals intake on top of QD Insulin Glargine, up to Week 26.

Group Type ACTIVE_COMPARATOR

Humalog

Intervention Type DRUG

Humalog 100 U/ml (dose range of 1 unit to 60 units) self-administered by SC injection, immediately (within 5-10 minutes) before meals intake. Dose adjusted to achieve a 2 hour PPG in range of 6.7 to 8.9 mmol/L (120 to 160 mg/dL) while avoiding hypoglycemia.

insulin glargine HOE901

Intervention Type DRUG

Insulin glargine 100 U/mL injected QD subcutaneously consistent with the local label. Doses adjusted to achieve glycemic target for fasting, preprandial plasma glucose (SMPG) between 4.4 to 7.2 mmol/L (80 to 130 mg/dL) without hypoglycemia.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

SAR342434

SAR342434 100 U/mL (dose range of 1 Unit to 80 Units) self-administered by subcutaneous (SC) injection, immediately (within 5 -10 minutes) before meals intake. Dose adjusted to achieve 2 hour post prandial glucose (PPG) in range of 6.7 to 8.9 mmol/L (120 to 160 mg/dL) while avoiding hypoglycemia.

Intervention Type DRUG

Humalog

Humalog 100 U/ml (dose range of 1 unit to 60 units) self-administered by SC injection, immediately (within 5-10 minutes) before meals intake. Dose adjusted to achieve a 2 hour PPG in range of 6.7 to 8.9 mmol/L (120 to 160 mg/dL) while avoiding hypoglycemia.

Intervention Type DRUG

insulin glargine HOE901

Insulin glargine 100 U/mL injected QD subcutaneously consistent with the local label. Doses adjusted to achieve glycemic target for fasting, preprandial plasma glucose (SMPG) between 4.4 to 7.2 mmol/L (80 to 130 mg/dL) without hypoglycemia.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Insulin Lispro Lantus®

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participants with T2DM diagnosed for at least 12 months and treated with insulin glargine and Humalog®/Liprolog® or NovoLog®/NovoRapid® (at least 3 times daily, before each meal) in the 6 months prior to the screening visit.
* Signed written informed consent.

Exclusion Criteria

* At screening visit, age under legal age of adulthood.
* HbA1c \<6.5% or \>10.0% at screening.
* Diabetes other than T2DM.
* Pregnancy and lactation.
* Women of childbearing potential not protected by highly effective contraceptive method of birth control.
* Use of insulin pump in the 6 months before screening visit.
* Use of insulin other than insulin glargine and Humalog or NovoLog/NovoRapid in the 6 months prior to screening visit. Liprolog® is an European Union (EU) approved insulin lispro and is allowed in those countries where it is marketed.
* Use of Humalog/Liprolog or Novolog/NovoRapid less than 3 times daily, before each meal.
* Use of non-injectable peptides (eg, Glucagon-like peptide-1 (GLP-1) receptor-agonists or other peptides) in the 6 months prior to screening visit.
* Body mass index (BMI) \>=40kg/m² at screening visit.
* Hospitalization for diabetic ketoacidosis in the last 6 months before screening visit.
* Unstable proliferative diabetic retinopathy or any other rapidly progressive diabetic retinopathy or macular edema likely to require treatment (eg, laser, surgical treatment, or injectable drugs) during the study period.
* The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Sanofi

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Clinical Sciences & Operations

Role: STUDY_DIRECTOR

Sanofi

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Investigational Site Number 840217

Foley, Alabama, United States

Site Status

Investigational Site Number 840237

Muscle Shoals, Alabama, United States

Site Status

Investigational Site Number 840245

Chandler, Arizona, United States

Site Status

Investigational Site Number 840219

Phoenix, Arizona, United States

Site Status

Investigational Site Number 840227

Phoenix, Arizona, United States

Site Status

Investigational Site Number 840212

Little Rock, Arkansas, United States

Site Status

Investigational Site Number 840241

El Cajon, California, United States

Site Status

Investigational Site Number 840238

Fresno, California, United States

Site Status

Investigational Site Number 840229

Greenbrae, California, United States

Site Status

Investigational Site Number 840231

Huntington Beach, California, United States

Site Status

Investigational Site Number 840247

Long Beach, California, United States

Site Status

Investigational Site Number 840234

Los Angeles, California, United States

Site Status

Investigational Site Number 840235

Northridge, California, United States

Site Status

Investigational Site Number 840251

Palm Springs, California, United States

Site Status

Investigational Site Number 840249

Santa Ana, California, United States

Site Status

Investigational Site Number 840223

Temecula, California, United States

Site Status

Investigational Site Number 840259

Tustin, California, United States

Site Status

Investigational Site Number 840240

Walnut Creek, California, United States

Site Status

Investigational Site Number 840214

Boynton Beach, Florida, United States

Site Status

Investigational Site Number 840246

Miami, Florida, United States

Site Status

Investigational Site Number 840226

New Port Richey, Florida, United States

Site Status

Investigational Site Number 840205

Ocoee, Florida, United States

Site Status

Investigational Site Number 840206

Palm Harbor, Florida, United States

Site Status

Investigational Site Number 840242

Port Charlotte, Florida, United States

Site Status

Investigational Site Number 840253

Lawrenceville, Georgia, United States

Site Status

Investigational Site Number 840207

Stockbridge, Georgia, United States

Site Status

Investigational Site Number 840248

Arlington Heights, Illinois, United States

Site Status

Investigational Site Number 840204

Avon, Indiana, United States

Site Status

Investigational Site Number 840257

Evansville, Indiana, United States

Site Status

Investigational Site Number 840230

Des Moines, Iowa, United States

Site Status

Investigational Site Number 840239

Rockville, Maryland, United States

Site Status

Investigational Site Number 840236

Troy, Michigan, United States

Site Status

Investigational Site Number 840216

Lincoln, Nebraska, United States

Site Status

Investigational Site Number 840220

Las Vegas, Nevada, United States

Site Status

Investigational Site Number 840233

Las Vegas, Nevada, United States

Site Status

Investigational Site Number 840224

Linden, New Jersey, United States

Site Status

Investigational Site Number 840232

Greensboro, North Carolina, United States

Site Status

Investigational Site Number 840211

Morehead City, North Carolina, United States

Site Status

Investigational Site Number 840228

Morganton, North Carolina, United States

Site Status

Investigational Site Number 840225

Fargo, North Dakota, United States

Site Status

Investigational Site Number 840221

Columbus, Ohio, United States

Site Status

Investigational Site Number 840255

Dayton, Ohio, United States

Site Status

Investigational Site Number 840250

Tipton, Pennsylvania, United States

Site Status

Investigational Site Number 840243

Uniontown, Pennsylvania, United States

Site Status

Investigational Site Number 840208

Chattanooga, Tennessee, United States

Site Status

Investigational Site Number 840215

Jackson, Tennessee, United States

Site Status

Investigational Site Number 840203

Austin, Texas, United States

Site Status

Investigational Site Number 840258

Dallas, Texas, United States

Site Status

Investigational Site Number 840201

Dallas, Texas, United States

Site Status

Investigational Site Number 840222

Renton, Washington, United States

Site Status

Investigational Site Number 840209

Milwaukee, Wisconsin, United States

Site Status

Investigational Site Number 032201

Caba, , Argentina

Site Status

Investigational Site Number 032206

Capital Federal, , Argentina

Site Status

Investigational Site Number 032202

Capital Federal, , Argentina

Site Status

Investigational Site Number 032205

Ciudad Autonoma de Buenos Aire, , Argentina

Site Status

Investigational Site Number 032203

Salta, , Argentina

Site Status

Investigational Site Number 152202

Santiago, , Chile

Site Status

Investigational Site Number 152204

Santiago, , Chile

Site Status

Investigational Site Number 152201

Santiago, , Chile

Site Status

Investigational Site Number 170203

Armenia, , Colombia

Site Status

Investigational Site Number 276201

Berlin, , Germany

Site Status

Investigational Site Number 276204

Heidelberg, , Germany

Site Status

Investigational Site Number 276202

Neumünster, , Germany

Site Status

Investigational Site Number 276206

Potsdam, , Germany

Site Status

Investigational Site Number 276205

Stuttgart, , Germany

Site Status

Investigational Site Number 276203

Sulzbach-Rosenberg, , Germany

Site Status

Investigational Site Number 348205

Budapest, , Hungary

Site Status

Investigational Site Number 348202

Budapest, , Hungary

Site Status

Investigational Site Number 348204

Debrecen, , Hungary

Site Status

Investigational Site Number 348208

Komárom, , Hungary

Site Status

Investigational Site Number 348210

Nagykanizsa, , Hungary

Site Status

Investigational Site Number 348209

Sátoraljaújhely, , Hungary

Site Status

Investigational Site Number 348203

Szolnok, , Hungary

Site Status

Investigational Site Number 380203

Bologna, , Italy

Site Status

Investigational Site Number 380201

Milan, , Italy

Site Status

Investigational Site Number 380204

Roma, , Italy

Site Status

Investigational Site Number 380202

Sesto San Giovanni, , Italy

Site Status

Investigational Site Number 642210

Bacau, , Romania

Site Status

Investigational Site Number 642201

Bucharest, , Romania

Site Status

Investigational Site Number 642202

Bucharest, , Romania

Site Status

Investigational Site Number 642206

Cluj-Napoca, , Romania

Site Status

Investigational Site Number 642204

Deva, , Romania

Site Status

Investigational Site Number 642205

Oradea, , Romania

Site Status

Investigational Site Number 642209

Sibiu, , Romania

Site Status

Investigational Site Number 642207

Târgu Mureş, , Romania

Site Status

Investigational Site Number 642208

Târgu Mureş, , Romania

Site Status

Investigational Site Number 642203

Timișoara, , Romania

Site Status

Investigational Site Number 643201

Saint Petersburg, , Russia

Site Status

Investigational Site Number 643203

Saint Petersburg, , Russia

Site Status

Investigational Site Number 643204

Saint Petersburg, , Russia

Site Status

Investigational Site Number 643202

Saint Petersburg, , Russia

Site Status

Investigational Site Number 643205

Saratov, , Russia

Site Status

Investigational Site Number 410202

Seoul, , South Korea

Site Status

Investigational Site Number 410204

Seoul, , South Korea

Site Status

Investigational Site Number 410205

Seoul, , South Korea

Site Status

Investigational Site Number 410201

Wŏnju, , South Korea

Site Status

Investigational Site Number 724201

Barcelona, , Spain

Site Status

Investigational Site Number 724203

Málaga, , Spain

Site Status

Investigational Site Number 724202

Palma de Mallorca, , Spain

Site Status

Investigational Site Number 792201

Istanbul, , Turkey (Türkiye)

Site Status

Investigational Site Number 792202

Istanbul, , Turkey (Türkiye)

Site Status

Investigational Site Number 792204

Izmir, , Turkey (Türkiye)

Site Status

Investigational Site Number 792203

Izmir, , Turkey (Türkiye)

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Argentina Chile Colombia Germany Hungary Italy Romania Russia South Korea Spain Turkey (Türkiye)

References

Explore related publications, articles, or registry entries linked to this study.

Derwahl KM, Bailey TS, Wernicke-Panten K, Ping L, Pierre S. Efficacy and Safety of Biosimilar SAR342434 Insulin Lispro in Adults with Type 2 Diabetes, Also Using Insulin Glargine: SORELLA 2 Study. Diabetes Technol Ther. 2018 Jan;20(1):49-58. doi: 10.1089/dia.2017.0281. Epub 2017 Dec 12.

Reference Type RESULT
PMID: 29232162 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2014-002844-42

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

U1111-1156-4296

Identifier Type: -

Identifier Source: secondary_id

EFC13403

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Lantus Versus Humalog Mix as add-on Therapy in Type Diabetes Patients Failing Sulfonylurea and Metformin Combination Treatment
NCT01336751 COMPLETED PHASE3
Evaluation of Insulin Glargine/Lixisenatide Fixed Ratio Combination in Patients With Type 2 Diabetes Insufficiently Controlled With Oral Antidiabetic Drug(s)
NCT03798054 COMPLETED PHASE3
Insulin Glargine in Type 2 Diabetes Mellitus
NCT00311818 COMPLETED PHASE4
A Comparative Study of LY900014 With Insulin Lispro (Humalog) in Participants With Type 2 Diabetes Mellitus (T2DM)
NCT03341312 COMPLETED PHASE1
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
NCT01499082 COMPLETED PHASE3
A Study of LY900014 Compared to Insulin Lispro (Humalog) in Adults With Type 2 Diabetes
NCT03952143 COMPLETED PHASE3
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy
NCT01676220 COMPLETED PHASE3
Comparison of Exposure and Activity of SAR341402 Mix 70/30 to NovoLog Mix 70/30, NovoMix 30 and SAR341402 Rapid-acting Solution in Patients With Type 1 Diabetes Mellitus
NCT03916601 COMPLETED PHASE1
Insulin Glargine Injection Treatment in Place of Thiazolidinedione (TZD), Sulfonylurea, or Metformin in Triple Agent Therapy for Type 2 Diabetes Mellitus (T2DM) Adult Subjects With Unsatisfactory Control
NCT00283049 TERMINATED PHASE4
Insulin Glulisine in Diabetes Mellitus, Type 2
NCT00174668 COMPLETED PHASE3
Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM
NCT02058147 COMPLETED PHASE3
Dose-Ranging, Pharmacokinetic (PK), Glucodynamic (GD), Safety and Tolerability Study of Subcutaneously (SC) Administered Humulin R and Humalog With or Without rHuPH20
NCT00803972 COMPLETED PHASE1
A Comparative Study of LY900014 to Insulin Lispro (Humalog) in Healthy Participants
NCT03286751 COMPLETED PHASE1
Insulin Glulisine, Insulin Lispro and Insulin Glargine in Type 1 or 2 Diabetes Mellitus
NCT00467376 COMPLETED PHASE3
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
NCT01499095 COMPLETED PHASE3
Insulin Glargine in Type 2 Diabetic Patients
NCT00347100 COMPLETED PHASE4
Pharmacokinetic (PK), Pharmacodynamic (PD), and Safety Study of Subcutaneously Administered Humalog® With and Without Recombinant Human Hyaluronidase (rHuPH20)and Humulin-R® With and Without rHuPH20
NCT00705536 COMPLETED PHASE1
A Study to Compare Pharmacokinetics (PK) and Pharmacodynamics (PD) of SAR341402 to Insulin Aspart in Subjects With Type 1 Diabetes Mellitus
NCT03202875 COMPLETED PHASE1
Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes
NCT02058160 COMPLETED PHASE3
The DURABLE Trial: Evaluating the Durability of Starter Insulin Regimens in Patients With Type 2 Diabetes (IOOV)
NCT00279201 COMPLETED PHASE4
Insulin Glulisine in Adult Subjects With Type 2 Diabetes Receiving Insulin Glargine as Basal Insulin
NCT00135057 COMPLETED PHASE3
Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period
NCT02787551 COMPLETED PHASE3
A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Glargine, in People With Type 2 Diabetes Who Have Not Used Insulin Before
NCT04460885 COMPLETED PHASE3
Evaluate Quality of Life in Type 2 Diabetes, Before and After Change to Insuline Glargine
NCT00518427 COMPLETED PHASE4
A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Glargine, Both in Combination With Mealtime Insulin, in People With Type 2 Diabetes Who Use Daily Insulin and Mealtime Insulin (ONWARDS 4)
NCT04880850 COMPLETED PHASE3